Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 1091-1100

  Kaminska, Bozena ^a   Ellert Miklaszewska, Aleksandra ^a   Oberbek, Agata ^a   Wisniewski, Pawel ^a   Kaza, Beata ^a   Makowska, Malgorzata ^b   Bretner, Maria ^b,c   Kazimierczuk, Zygmunt ^d,e  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^e WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Casein kinase 2 inhibitors; Glioblastoma

Indexed keywords

2 DIMETHYLAMINO 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 3 (4,5,6,7 TETRABROMO 1H 1,2,3 BENZOTRIAZOL 1 YL)PROPAN 1 OL; 3 (4,5,6,7 TETRABROMO 1H BENZIMIDAZOL 1 YL)PROPAN 1 OL; 3 (4,5,6,7 TETRABROMO 2H 1,2,3 BENZOTRIAZOL 2 YL)PROPAN 1 OL; 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 4,5,6,7 TETRABROMO 1H BENZOTRIAZOLE; CASEIN KINASE II; CASPASE 3; CASPASE 7; FAS LIGAND; MB 001; MB 002; MB 003; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PENTABROMOBENZYLISOTHIOUREA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; POLYMERASE CHAIN REACTION; RATS;

EID: 70449585521     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000424     Document Type: Article

References (52)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
2. Ohgaki H and Kleihaus P: Epidemiology and etiology of gliomas. Acta Neuropathol 109: 93-108, 2005.
3. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC and Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytomas and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001. (Pubitemid 32816199)
4. Smith JS and Jenkins RB: Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 5: 213-231, 2000.
5. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG and Aldape K: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61: 1122-1128, 2001. (Pubitemid 32174434)
6. Zupanska A and Kaminska B: The diversity of p53 mutations among human brain tumors and their functional consequences. Neurochem Int 40: 637-645, 2002. (Pubitemid 34246242)
7. Meggio F and Pinna LA: One-thousand-and-one substrates of protein kinase CK2? FASEB J 17: 349-368, 2003.
8. Litchfield DW: Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369: 1-15, 2003.
9. Duncan JS and Litchfield DW: Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784: 33-47, 2008.
10. Pepperkok R, Lorenz P, Ansorge W and Pyerin W: Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J Biol Chem 269: 6986-6991, 1994.
11. Lorenz P, Pepperkok R and Pyerin W: Requirement of casein kinase 2 for entry into and progression through early phases of the cell cycle. Cell Mol Biol Res 40: 519-527, 1994.
12. Sayed M, Pelech S, Wong C, Marotta A and Salh B: Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells. Oncogene 20: 6994-7005, 2001. (Pubitemid 33052192)
13. Wang H, Davis A, Yu S and Ahmed K: Response of cancer cells to molecular interruption of the CK2 signal. Mol Cell Biochem 227: 167-174, 2001. (Pubitemid 34048381)
14. Wang G, Unger G, Ahmad KA, Slaton JW and Ahmed K: Downregulation of CK2 induces apoptosis in cancer cells - a potential approach to cancer therapy. Mol Cell Biochem 274: 77-84, 2005. (Pubitemid 41001503)
15. Sarno S and Pinna LA: Protein kinase CK2 as druggable target. Mol Biosyst 4: 889-894, 2008.
16. Ruzzene M, Penzo D and Pinna LA: Protein kinase CK2 inhibitor 4, 5, 6, 7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41-47, 2002.
17. Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N and Groffen J: Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 22: 8255-8262, 2003. (Pubitemid 37485518)
18. Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, Kazimierczuk Z, Pinna LA and Heisterkamp N: Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/ threonine kinase CK2. Leukemia 21: 178-180, 2007. (Pubitemid 44921853)
19. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA and Ruzzene M: Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 26: 6915-6926, 2007. (Pubitemid 47609076)
20. Di Maira G, Brustolon F, Tosoni K, Belli S, Krämer SD, Pinna LA and Ruzzene M: Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. Mol Cell Biochem 316: 155-161, 2008.
21. Tapia JC, Torres VA, Rodriquez DA, Leyton L and Quest AF: Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA 103: 15079-15084, 2006. (Pubitemid 44583167)
22. Hamacher R, Saur D, Fritsch R, Reichert M, Schmid RM and Schneider G: Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol Rep 18: 695-701, 2007.
23. Hessenauer A, Montenarh M and Gotz C: Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 22: 1263-1270, 2006.
24. Yde CW, Frogne T, Lykkesfeldt AE, Fichtner I, Issinger OG, and Stenvang J: Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett 256: 229-237, 2007. (Pubitemid 47418349)
25. Battistutta R, De Moliner E, Sarno S, Zanotti G and Pinna LA: Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci 10: 2200-2206, 2001. (Pubitemid 32988637)
26. Pagano MA, Bain J, Kazimierczuk Z, Sarno S, Ruzzene M, Di Maira G, Elliott M, Orzeszko A, Cozza G, Meggio F and Pinna LA: The selectivity of inhibitors of protein kinase CK2: an update. Biochem J 415: 353-365, 2008.
27. Mazzorana M, Pinna LA and Battistutta R: A structural insight into CK2 inhibition. Cell Biochem 316: 57-62, 2008.
28. Diaz-Nido J, Mizuno K, Nawa H and Marshak DR: Regulation of protein kinase CK2 isoform expression during rat brain development. Cell Mol Biol Res 140: 581-585, 1994.
29. Maccario H, Perera NM, Davidson L, Downes CP and Leslie NR: PTEN is destabilized by phosphorylation on Thr366. Biochem J 405: 439-444, 2007.
30. Bretner M, Najda-Bernatowicz A, Lebska M, Muszynska G, Kilanowicz A and Sapota A: New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole. Mol Cell Biochem 316: 87-89, 2008.
31. Najda-Bernatowicz A, Lebska M, Orzeszko A, Kopanska K, Krzywinska E, Muszynska G and Bretner M: Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide-potential inhibitors of human protein kinase CK2. Bioorg Med Chem 17: 1573-1578, 2009.
32. Zien P, Bretner M, Zastapilo K, Szyszka R and Shugar D: Selectivity of 4, 5, 6, 7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. Biochem Biophys Res Commun 306: 129-133, 2003.
33. Zien P, Duncan JS, Skierski J, Bretner M, Litchfield DW and Shugar D: Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim Biophys Acta 1754: 271-280, 2005. (Pubitemid 41797708)
34. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z and Pinna LA: 2-Dimethylamino-4, 5, 6, 7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321: 1040-1044, 2004.
35. Iwai N, Nagai K and Wachi M: Novel S-benzylisothiourea compound that induces spherical cells in Escherichia coli probably by acting on a rod-shape-determining protein(s) other than penicillin-binding protein 2. Biosci Biotechnol Biochem 66: 2658-2662, 2002.
36. Szydlowska K, Zawadzka M and Kaminska B: Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo. J Neurochem 99: 965-975, 2006. (Pubitemid 44583453)
37. Ellert-Miklaszewska A, Kaminska B and Konarska L: Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17: 25-37, 2005. (Pubitemid 39286777)
38. Zupanska A, Dziembowska M, Ellert-Miklaszewska A, Gaweda-Walerych K and Kaminska B: Cyclosporine A induces growth arrest or programmed cell death of human glioma cells. Neurochem Int 47: 430-441, 2005. (Pubitemid 41242624)
39. Duncan JS, Gyenis L, Lenehan J, Bretner M, Graves LM, Haystead TA and Litchfield DW: An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteomics 7: 1077-1088, 2008. (Pubitemid 351943955)
40. Khidr L and Chen PL: RB, the conductor that orchestrates life, death and differentiation. Oncogene 25: 5210-5219, 2006. (Pubitemid 44299079)
41. Lundberg AS and Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761, 1998.
42. Salvesen GS and Dixit VM: Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 96: 10964-10967, 1999.
43. Bao Q and Shi Y: Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 14: 56-65, 2007. (Pubitemid 44911894)
44. Riedl SJ and Salvesen GS: The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8: 405-413, 2007.
45. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
46. Reed J: Apoptosis-based therapies. Nat Rev Drug Discov: 111-121, 2002.
47. Kroemer G and Reed JC: Mitochondrial control of cell death. Nat Med 6: 513-519, 2000.
48. Steinbach JP and Weller M: Apoptosis in gliomas: molecular mechanisms and therapeutic implications. J Neurooncol 70: 245-254, 2004. (Pubitemid 39545735)
49. Ziegler DS, Kung AL and Kieran MW: Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26: 493-500, 2008.
50. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for cancer. Oncogene 27: 6252-6275, 2008.
51. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X and Harran PG: A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305: 1471-1474, 2004. (Pubitemid 39167668)
52. Fabian MA, Biggs WH III, Treiber DK, et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336, 2005.